Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
290 Leser
Artikel bewerten:
(1)

GHO Capital acquires Scientist.com, the leading AI-powered R&D orchestration platform

GHO Capital acquires Scientist.com, the leading AI-powered R&D orchestration platform

Transaction underscores GHO's strategy of backing category leaders across preclinical and clinical R&D services

Scientist.com is the market-leading digital platform for outsourced R&D, trusted by the world's top biopharma companies and thousands of pre-vetted suppliers of scientific services and products.

• GHO's deep sector knowledge and proven record of scaling life sciences businesses will accelerate Scientist.com's next phase of global growth.

London, UK - 16 September 2025: GHO Capital Partners LLP ("GHO"), the specialist investor in global healthcare, today announces it has entered into a definitive agreement to acquire Scientist.com, the AI-powered R&D orchestration platform that enables pharmaceutical and biotech companies to source and manage outsourced research from a global network of pre-approved suppliers.

The acquisition expands GHO's portfolio of category-leading companies delivering innovative solutions that improve efficiency, compliance, and impact across healthcare and life sciences. Scientist.com's sector focus on pharmaceutical R&D services, biotechnology, life science tools, and contract research aligns directly with GHO's areas of deep expertise. Together, the partnership creates powerful synergies to fuel Scientist.com's expansion through global reach, strategic partnerships, and selective acquisitions.

Biopharma R&D procurement processes remain fragmented and manual, creating inefficiencies and compliance risks, particularly in highly regulated, complex research and clinical markets. Scientist.com solves this by connecting pharmaceutical and biotech companies to a curated, global network of pre-vetted suppliers on one intelligent platform. At its core is a powerful AI engine that streamlines the entire outsourced research process - from supplier qualification and compliance enforcement to intelligent vendor matching, automated contract drafting, predictive project modelling, and smart negotiation tools - within one seamless platform. Created by scientists for scientists, the platform accelerates high-value R&D while navigating the realities of complex procurement, transforming how organisations source innovation.

Edward de Nor and Stuart Quin, Partners at GHO, said: "Scientist.com is a category-defining platform that transforms how biopharma companies manage R&D procurement, seamlessly integrating software, data, and outsourced services. The alignment between our expertise in pharmaceutical R&D, biotechnology, and life science tools, and Scientist.com's market leadership, creates a unique opportunity to accelerate its growth. We are excited to partner with the team to expand global adoption and advance innovation, in line with our mission to deliver better, faster, more accessible healthcare."

Kevin Lustig, PhD, Andy Martin, PhD and Chris Petersen, Founders of Scientist.com, commented: "GHO's expertise across our key market segments and track record of scaling innovative leaders make them the ideal partner to help us scale globally. Together, we can put outsourced R&D 'on rails', delivering shorter timelines, stronger governance, and clearer visibility from concept to clinic."

Based in Solana Beach, California, Scientist.com is a global leader in life sciences R&D procurement, trusted by the world's largest pharmaceutical companies, hundreds of biotech firms, and thousands of suppliers. The platform provides an end-to-end compliance solution that unifies supplier discovery, bidding, contracting, compliance, and spend analytics within a secure ecosystem. This enables users to achieve double-digit percentage cost savings while cutting project timelines from months to days. With a first-mover advantage and over a decade of growth, Scientist.com is the trusted partner for companies seeking to optimise their external R&D procurement.

Advisors

GHO was advised by Ropes & Gray, ClearView Healthcare Partners, West Monroe, and Deloitte.

Scientist.com was advised by Union Square Advisors and Wilson Sonsini.

Further information:

GHO Capital Partners LLP

T +44 20 3700 7440

E IR@ghocapital.com

For Media Enquiries:

ICR Healthcare Tel: +44

Amber Fennell, Kris Lam

About GHO Capital

Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor headquartered in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market-leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.

About Scientist.com

Scientist.com is the leading AI-enabled R&D orchestration platform for the life science industry. The platform simplifies drug discovery and clinical development by streamlining procurement, accelerating innovation, ensuring regulatory compliance and connecting scientists with a global network of pre-qualified suppliers. Scientist.com powers private marketplaces for many of the world's largest pharmaceutical companies and hundreds of biotech firms. The company is headquartered in Solana Beach, California. For more information, please visit www.scientist.com.


© 2025 GlobeNewswire (Europe)
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.